Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study - Poll - MDSpire

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

  • By

  • Neeltje Steeghs

  • Carlos Gomez-Roca

  • Iphigénie Korakis

  • Eelke Gort

  • Hilde De Winter

  • Nina Stojcheva

  • Vaia Stavropoulou

  • Jennifer Krieg

  • Paul Baverel

  • Elena Fernandez

  • Ana Maria Florescu

  • Lea Hoenig

  • Michael Peter Sanderson

  • Vladimir Kirkin

  • Philippe Legenne

  • Philippe Alexandre Cassier

  • May 1, 2026

  • 0 min

Share

Original Source(s)

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

  • by Neeltje Steeghs, Carlos Gomez-Roca, Iphigénie Korakis, Eelke Gort, Hilde De Winter, Nina Stojcheva, Vaia Stavropoulou, Jennifer Krieg, Paul Baverel, Elena Fernandez, Ana Maria Florescu, Lea Hoenig, Michael Peter Sanderson, Vladimir Kirkin, Philippe Legenne, Philippe Alexandre Cassier

  • May 1, 2026

Related Content

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases